Astrazeneca (AZN) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?
AstraZeneca upgrade (of sorts) by leading investment bank
AstraZeneca PLC (LSE:AZN) has been upgraded by a leading investment bank following guidance on the company's dividend policy, and a more positive earnings outlook. Deutsche Bank has moved to 'hold'...
3 Pharma Stocks That Are Money-Printing Machines in 2024
The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in...
AstraZeneca: A case of steady-as-she-goes, says broker
AstraZeneca PLC (LSE:AZN) is poised to maintain its full-year financial guidance without adjustments when it announces its first-quarter results later this month (April 25), according to insights f...
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
Was AstraZeneca boss Soriot's pay rise controversial? Not particularly
It was framed as a pitched battle between two opposing camps in AstraZeneca PLC (LSE:AZN)'s shareholder base. On one side, chief executive Pascal Soriot's 11% annual remuneration hike was egregious...
AstraZeneca shareholders approve £18.7mln CEO pay package
AstraZeneca PLC (LSE:AZN) shareholders approved a controversial increase to chief executive Pascal Soriot's pay package yesterday. Over 78% of votes gave the £18.7 million salary and bonus package ...
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session.
AstraZeneca offers 7% dividend sweetener on day of crucial pay vote
AstraZeneca PLC (LSE:AZN) has increased its annual dividend by 7%, bringing it up to $3.10 (£2.5) per share. It marks the highest annual dividend increase in recent years, having only shifted from ...
AstraZeneca pay debate exposes disparity in US-UK corporate values
Tomorrow's shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot's compensation represents a microcosm of the broader debate around executive entitlement and the disparity in corporate v...
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.
AstraZeneca cancer trial readout underlines immuno opportunity, suggests broker
AstraZeneca positive data from Imfinzi's Phase III ADRIATIC trial follows the raft of positive readouts and approvals across a range of cancer types, notes Shore Capital. Already these have stimula...
AstraZeneca reports 'significant' patient improvement in latest Imfinzi cancer trial
AstraZeneca has reported that Imfinzi significantly improved survival rates in the latest trial of the immunotherapy-based blockbuster cancer drug. Results from the Phase III ADRIATIC study in peop...
Related Companies